CT-P6

Phase 3Small molecule

CCelltrion

CT-P6 is one of 19 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Breast CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Gemzar

GGynecologic Oncology Group

Preclinical

22 3

CT-P6

CCelltrion

Phase 3

1 4

Adenocard

Astellas

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Acupan

YYonsei University

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy1 trial

Evaluate Safety, Efficacy and Pharmacokinetics

Completed·CCelltrion·Phase 1/2·NCT01084863·143 enrolled

Breast Cancer1 trial

Demonstrate Efficacy and Safety of Metastatic Breast Cancer

Completed·CCelltrion·Phase 3·NCT01084876·475 enrolled

Immunogenicity1 trial

To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)

Active, not recruiting·CCelltrion·Phase 1·NCT06687928·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for CT-P6. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CT-P6 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CT-P6. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celltrion company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCelltrion

CT-P6

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy1 trial

Breast Cancer1 trial

Immunogenicity1 trial

References

Drug Info

Quick Facts

Related News